Last reviewed · How we verify

A Phase 1 Study to Estimate MMAE Metabolites in Human Plasma and Urine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma or Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Receiving Brentuximab Vedotin

NCT01950364 Phase 1 COMPLETED Results posted

This is an open-label trial to estimate the concentrations of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma (HL) or relapsed/refractory systemic anaplastic large cell lymphoma (sALCL) participants treated with either brentuximab vedotin or brentuximab vedotin + rifampicin.

Details

Lead sponsorMillennium Pharmaceuticals, Inc.
PhasePhase 1
StatusCOMPLETED
Enrolment20
Start date2013-11
Completion2015-06

Conditions

Interventions

Primary outcomes

Countries

Belgium, Lithuania, Spain